CRISPR Therapeutics AG — Director's Dealing 2019

Jun 13, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2019-06-11

Reporting Person: Greene John (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$36.80	2028-11-02	Common Shares (10000)		Direct

Footnotes

F1: This option was granted on November 2, 2018 with respect to 10,000 Common Shares, with 100% of the shares vesting in 16 equal quarterly installments over a four-year period, beginning on November 2, 2018.